Form 4: Gossamer Bio COO/CFO Stock Options Repriced to $0.45

Gossamer Bio's COO/CFO Bryan Giraudo had a significant portion of his outstanding stock options repriced to an exercise price of $0.45 per share.

Summary

• Bryan Giraudo, the Chief Operating Officer and Chief Financial Officer of Gossamer Bio, Inc. (GOSS), reported a one-time repricing of certain outstanding stock options.
• Effective March 19, 2026, the exercise price for these options, granted under the Issuer's 2019 Incentive Award Plan, was reduced to $0.45 per share.
• The repricing affected a total of 2,961,251 stock options, which previously had exercise prices ranging from $0.838 to $2.88.
• All other terms and conditions of the repriced options, including vesting schedules and expiration dates, remain unchanged.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for shareholders, as option repricing typically signals significant stock underperformance and can raise corporate governance concerns.

Positives

• The repricing significantly reduces the exercise price of a large number of stock options for the COO/CFO, potentially increasing their intrinsic value and re-establishing incentive.
• The new exercise price of $0.45 is substantially lower than the original exercise prices, which were as high as $2.88.

Negatives

• Stock option repricing is often viewed negatively by shareholders as it can dilute their holdings and suggests that the company's stock price has significantly underperformed, rendering original options underwater.
• This action may raise corporate governance concerns regarding management accountability for past stock performance and the fairness of executive compensation practices.

Risks

• Potential negative investor sentiment due to the perception of management being rewarded despite stock underperformance, which could impact the company's share price.
• Concerns about potential future shareholder dilution if the repriced options are exercised, although the repricing itself does not create new shares.
• The need for repricing implies a significant decline in the company's stock value, signaling underlying business or market challenges for Gossamer Bio.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the terms of the repriced options.

Management Comments

• Effective as of March 19, 2026 (the 'Repricing Date'), the Issuer approved a one-time repricing of certain outstanding stock options (the 'Repriced Options') granted under the Issuer's 2019 Incentive Award Plan (the '2019 Plan'), which reduced the per share exercise price of each Repriced Option to $0.45 (the 'Option Repricing').
• Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
• This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Industry Context

StockSavvy.ai notes that option repricing is a practice often employed by companies whose stock price has significantly underperformed, rendering existing options underwater and ineffective as an incentive. While it can re-motivate executives, it frequently draws criticism from shareholders concerned about dilution and perceived unfairness, especially when competitors maintain more stringent equity compensation policies.

Comparison to Industry Standards

• Option repricing is generally viewed as a shareholder-unfriendly practice by corporate governance advocates and institutional investors, contrasting with best practices that emphasize performance-based vesting and avoiding repricing to align management incentives with long-term shareholder value.
• Companies like Apple or Microsoft rarely engage in option repricing, preferring to issue new grants at current market prices or use performance-based restricted stock units (RSUs) to incentivize executives, which better aligns with shareholder interests.
• In the biotechnology sector, where Gossamer Bio operates, stock volatility is common. However, frequent or significant repricing can signal deeper issues with company performance or strategy compared to peers who manage to retain executive talent without such measures.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and concerns over corporate governance and management accountability for stock performance.
• Management (reporting person): Significant positive impact as the intrinsic value of their options increases, restoring incentive.

Key Dates

Recommendation

The repricing of executive stock options, while beneficial for the COO/CFO, signals past stock underperformance and raises corporate governance questions. Investors should hold and monitor the company's future performance and broader compensation practices, as this event alone doesn't warrant an immediate sell, but it does introduce a cautionary note regarding management's alignment with shareholder value.

Keywords

Gossamer Bio, GOSS, Stock Options, Repricing, Executive Compensation, Form 4, Insider Transaction, Bryan Giraudo, Equity Compensation, Corporate Governance